Daunorubicin can eliminate iPS-derived cancer stem cells via ICAD/CAD-independent DNA fragmentation
作者机构：Laboratory of Nano-BiotechnologyGraduate School of Interdisciplinary Science and Engineering in Health SystemsOkayama UniversityOkayama 700-8530Japan Division of Medical BioengineeringGraduate School of Natural Science and TechnologyOkayama UniversityOkayama 700-8530Japan.
出 版 物：《Cancer Drug Resistance》 (癌症耐药（英文）)
年 卷 期：2019年第2卷第2期
页 面：335-350页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：Japan Chemical Industry Association, JCIA, (24501315) Ministry of Education, Culture, Sports, Science and Technology, MEXT Ministerio de Educación, Cultura y Deporte, MECD
主 题：Daunorubicin cancer stem cell DNA fragmentation
摘 要：Aim:To identify a drug that can effectively eliminate these cancer stem cells(CSCs)and determine its mode of ***:CSCs were obtained from mouse induced pluripotent stem cells(miPSCs)using cancer cell-conditioned *** screening was performed on these cells or after transplantation into *** was analyzed by flow cytometry and western ***:Drug screening studies showed that daunorubicin,a topoisomerase II inhibitor,is specifically cytotoxic to ***-induced apoptosis was found to be associated with p53 accumulation,activation of the caspase cascade,and oligonucleosomal DNA *** with the caspase inhibitor abolished daunorubicin-induced DNA fragmentation and was therefore considered to act downstream of caspase *** was also suppressed by treatment with a Ca2+-specific chelator,which suggested that CAD endonuclease does not ***,no obvious ICAD reduction/degradation was ***:Daunorubicin effectively eliminated CSCs,which are dependent on the p53/caspase signaling *** current findings provided the basis for further studies on CSC-targeted drugs for the development of cancer treatment strategies.
维普期刊数据库